Bill Gross warns on gold momentum as regional bank stocks tumble
DUBLIN - BlackRock, Inc. has disclosed a 1.63% stake in Mural Oncology plc, according to a regulatory filing published Friday.
The investment management firm reported ownership of 284,060 shares in the oncology company, based on an Irish Takeover Panel opening position disclosure. The position includes 284,045 relevant securities owned or controlled and 15 shares through cash-settled derivatives.
The disclosure, made under Rule 8.3 of the Irish Takeover Panel Act, is required when an entity holds interests in relevant securities representing 1% or more during an offer period.
BlackRock’s filing indicates the position was held as of September 18, 2025. The document also shows the firm has no short positions in Mural Oncology securities.
The filing further reveals a transaction involving the return of 1,200 shares on loan, though no price was specified for this transaction.
Companies are required to disclose such positions to provide transparency during potential takeover situations. The disclosure was submitted to the Regulatory Information Service as mandated by Irish takeover regulations.
The filing does not indicate any indemnity arrangements or agreements relating to options or derivatives regarding Mural Oncology securities.
Based on the regulatory filing, BlackRock’s stake represents a significant position in Mural Oncology, which specializes in cancer treatments and therapeutics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.